These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 25605241)

  • 21. High expression of the long non-coding RNA HEIRCC promotes Renal Cell Carcinoma metastasis by inducing epithelial-mesenchymal transition.
    Xiong J; Liu Y; Luo S; Jiang L; Zeng Y; Chen Z; Shi X; Lv B; Tang W
    Oncotarget; 2017 Jan; 8(4):6555-6563. PubMed ID: 28030807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High expression of fructose-bisphosphate aldolase A induces progression of renal cell carcinoma.
    Huang Z; Hua Y; Tian Y; Qin C; Qian J; Bao M; Liu Y; Wang S; Cao Q; Ju X; Wang Z; Gu M
    Oncol Rep; 2018 Jun; 39(6):2996-3006. PubMed ID: 29693182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SPOP promotes tumor progression via activation of β-catenin/TCF4 complex in clear cell renal cell carcinoma.
    Zhao W; Zhou J; Deng Z; Gao Y; Cheng Y
    Int J Oncol; 2016 Sep; 49(3):1001-8. PubMed ID: 27572476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of reptin in renal cell carcinoma contributes to tumor malignancies and its inhibition triggers senescence of cancer cells.
    Ren J; Li W; Liu H; Yan L; Jiao W; Li D; Tang Y; Gu G; Xu Z
    Urol Oncol; 2013 Oct; 31(7):1358-66. PubMed ID: 22341977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor suppressive microRNA‑138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma.
    Yamasaki T; Seki N; Yamada Y; Yoshino H; Hidaka H; Chiyomaru T; Nohata N; Kinoshita T; Nakagawa M; Enokida H
    Int J Oncol; 2012 Sep; 41(3):805-17. PubMed ID: 22766839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.
    Sureban SM; Madhoun MF; May R; Qu D; Ali N; Fazili J; Weygant N; Chandrakesan P; Ding K; Lightfoot SA; Houchen CW
    Oncotarget; 2015 Nov; 6(35):37200-15. PubMed ID: 26468984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
    Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
    Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and prognostic significance of a comprehensive epithelial-mesenchymal transition gene set in renal cell carcinoma.
    Chen D; Gassenmaier M; Maruschke M; Riesenberg R; Pohla H; Stief CG; Zimmermann W; Buchner A
    J Urol; 2014 Feb; 191(2):479-86. PubMed ID: 24012533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia-induced downregulation of miR-30c promotes epithelial-mesenchymal transition in human renal cell carcinoma.
    Huang J; Yao X; Zhang J; Dong B; Chen Q; Xue W; Liu D; Huang Y
    Cancer Sci; 2013 Dec; 104(12):1609-17. PubMed ID: 24112779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epithelial-mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma.
    Yoshino H; Enokida H; Itesako T; Tatarano S; Kinoshita T; Fuse M; Kojima S; Nakagawa M; Seki N
    J Hum Genet; 2013 Aug; 58(8):508-16. PubMed ID: 23635949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knockdown of NSD2 Suppresses Renal Cell Carcinoma Metastasis by Inhibiting Epithelial-Mesenchymal Transition.
    Han X; Piao L; Yuan X; Wang L; Liu Z; He X
    Int J Med Sci; 2019; 16(10):1404-1411. PubMed ID: 31692936
    [No Abstract]   [Full Text] [Related]  

  • 32. DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer.
    Gao T; Wang M; Xu L; Wen T; Liu J; An G
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2131-40. PubMed ID: 27520310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
    Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
    Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
    Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoplasmic expression of pontin in renal cell carcinoma correlates with tumor invasion, metastasis and patients' survival.
    Zhang X; Ren J; Yan L; Tang Y; Zhang W; Li D; Zang Y; Kong F; Xu Z
    PLoS One; 2015; 10(3):e0118659. PubMed ID: 25751257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NDRG2 is involved in the oncogenic properties of renal cell carcinoma and its loss is a novel independent poor prognostic factor after nephrectomy.
    Liang ZL; Kang K; Yoon S; Huang SM; Lim JS; Kim JM; Lim JS; Lee HJ
    Ann Surg Oncol; 2012 Aug; 19(8):2763-72. PubMed ID: 22246425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CSN5 promotes renal cell carcinoma metastasis and EMT by inhibiting ZEB1 degradation.
    Zhang S; Hong Z; Chai Y; Liu Z; Du Y; Li Q; Liu Q
    Biochem Biophys Res Commun; 2017 Jun; 488(1):101-108. PubMed ID: 28479251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of let-7e gene expression attenuates oncogenic phenotype in HCT-116 colorectal cancer cells through targeting of DCLK1 regulation.
    Khodadadi Kohlan A; Saidijam M; Amini R; Samadi P; Najafi R
    Life Sci; 2019 Jul; 228():221-227. PubMed ID: 31075231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LINC00961 restrains cancer progression via modulating epithelial-mesenchymal transition in renal cell carcinoma.
    Chen D; Zhu M; Su H; Chen J; Xu X; Cao C
    J Cell Physiol; 2019 May; 234(5):7257-7265. PubMed ID: 30367453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DCLK1 integrates induction of TRIB3, EMT, drug resistance and poor prognosis in colorectal cancer.
    Makino S; Takahashi H; Okuzaki D; Miyoshi N; Haraguchi N; Hata T; Matsuda C; Yamamoto H; Mizushima T; Mori M; Doki Y
    Carcinogenesis; 2020 May; 41(3):303-312. PubMed ID: 31562741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.